Enhancing glycosuria, through SGLT2 inhibition (Rossetti et al., 1987; Oku et al., 1999; Han et al., 2008), is now used to reduce blood glucose levels in humans with diabetes. The gene discussed is SLC5A2; the disease is diabetes mellitus.